USA flag logo/image

An Official Website of the United States Government

SBIR TOPIC 252 -COMMERCIALLY VIABLE SYNTHESIS OF MULTIFUNCTIONAL CANCER RECEPTOR

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
94151
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
N43CO0800057
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NANOPARTICLE BIOCHEM, INC.
2814 WILD PLUM CT. COLUMBIA, MO 65201-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: SBIR TOPIC 252 -COMMERCIALLY VIABLE SYNTHESIS OF MULTIFUNCTIONAL CANCER RECEPTOR
Agency: HHS
Contract: N43CO0800057
Award Amount: $135,973.00
 

Abstract:

In this Phase I SBIR contract, Nanoparticle Biochem Inc (NBI) proposes to develop commercially viable synthetic methodology for the production of multifunctional gold Nanoparticle-bombesin conjugate. Gold Nanoparticle-bombesin (AuNP-BBN) conjugate is a pot ential clinical imaging and therapeutic agent for the detection and treatment of GRP receptors over-expressing prostate and breast cancers. Average size of AuNP-BBN nanoconjugates are 14 nm. AuNP-BBN conjugate was developed by the funds from NCI's cancer n anoscience and nanotechnology platform grant and it is licensed to Nanoparticle Biochem Inc. Currently available methodology can yield only 10 mg quantities of AuNP-BBN. Developing a commercially-viable strategy for synthesizing AuNP-BBN nanoconjugate woul d significantly help in performing preclinical cancer imaging efficacy studies in larger animal models and preclinical toxicity studies.

Principal Investigator:

Anandhi Upendran

Business Contact:

Small Business Information at Submission:

NANOPARTICLE BIOCHEM, INC.
2814 WILD PLUM CT. COLUMBIA, MO 65201

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No